Skip to Main Content

It’s been two years since Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) secured approval for a new and highly effective treatment for people suffering with a serious form of eczema. In that time, the Regeneron-Sanofi drug, called Dupixent, has grown into a commercial blockbuster.

On Monday, Dermira (DERM), a small biotech firm based on Menlo Park, Calif., announced clinical trial results for a new drug called lebrikizumab that alleviated the signs and symptoms of serious eczema far greater than a placebo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!